Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Senzer

Showing results (11-20 of 75) with videos related to

Pageof 8
Sort By:
Expert Opinion on Biological Therapy|November 1, 2005
Individualised cancer therapeutics: dream or reality? Therapeutics constructionYuqiao Shen, Neil Senzer, John Nemunaitis
Expert Opinion on Therapeutic Targets|November 23, 2005
Individualised cancer therapeutics: dream or reality?Neil Senzer, Yuqiao Shen, Colin Hill, et al.
American Journal of Surgery|July 4, 2002
Conservative surgery and radiation therapy for macroscopically multiple ipsilateral invasive breast cancersL Chinsoo Cho, Neil Senzer, George N Peters
ISRN Oncology|April 24, 2012
Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced DiseaseOlivia Simmons, Phillip B Maples, Neil Senzer, et al.
Pharmaceutical Research|October 20, 2011
RNA interference and cancer therapyZhaohui Wang, Donald D Rao, Neil Senzer, et al.
Discovery Medicine|March 2, 2013
RNA interference and personalized cancer therapyDonald D Rao, Zhaohui Wang, Neil Senzer, et al.
Expert Review of Anticancer Therapy|September 2, 2008
Stathmin 1: a novel therapeutic target for anticancer activityShushan Rana, Phillip B Maples, Neil Senzer, et al.
Advanced Drug Delivery Reviews|April 25, 2009
siRNA vs. shRNA: similarities and differencesDonald D Rao, John S Vorhies, Neil Senzer, et al.
American Journal of Clinical Oncology|February 3, 2005
Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trialNeil Senzer, James Arsenau, Donald Richards, et al.
Current Gene Therapy|March 12, 2009
Systemic therapeutic gene delivery for cancer: crafting Paris' arrowAlex W Tong, Chris M Jay, Neil Senzer, et al.
Pageof 8

Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
Expert Opinion on Biological Therapy|November 1, 2005
Individualised cancer therapeutics: dream or reality? Therapeutics constructionYuqiao Shen, Neil Senzer, John Nemunaitis
Expert Opinion on Therapeutic Targets|November 23, 2005
Individualised cancer therapeutics: dream or reality?Neil Senzer, Yuqiao Shen, Colin Hill, et al.
American Journal of Surgery|July 4, 2002
Conservative surgery and radiation therapy for macroscopically multiple ipsilateral invasive breast cancersL Chinsoo Cho, Neil Senzer, George N Peters
ISRN Oncology|April 24, 2012
Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced DiseaseOlivia Simmons, Phillip B Maples, Neil Senzer, et al.
Pharmaceutical Research|October 20, 2011
RNA interference and cancer therapyZhaohui Wang, Donald D Rao, Neil Senzer, et al.
Discovery Medicine|March 2, 2013
RNA interference and personalized cancer therapyDonald D Rao, Zhaohui Wang, Neil Senzer, et al.
Expert Review of Anticancer Therapy|September 2, 2008
Stathmin 1: a novel therapeutic target for anticancer activityShushan Rana, Phillip B Maples, Neil Senzer, et al.
Advanced Drug Delivery Reviews|April 25, 2009
siRNA vs. shRNA: similarities and differencesDonald D Rao, John S Vorhies, Neil Senzer, et al.
American Journal of Clinical Oncology|February 3, 2005
Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trialNeil Senzer, James Arsenau, Donald Richards, et al.
Current Gene Therapy|March 12, 2009
Systemic therapeutic gene delivery for cancer: crafting Paris' arrowAlex W Tong, Chris M Jay, Neil Senzer, et al.
Pageof 8